(Reuters) - Johnson & Johnson is coming under fire from some investors who are raising questions about companies that give their chief executives hefty pay raises despite facing billions of dollars in legal costs over their role in the U.S. opioid crisis.
Updated On: 29 Mar 2021 | 4:51 PM IST